Patent and Trademark News

MINNEAPOLIS, Minn., Nov. 19 (SEND2PRESS NEWSWIRE) -- Minnesota Medical Development, Inc. (MMDI) today announced that the United States Patent and Trademark Office has issued a Notice of Allowance for the company's BetaWire(TM) guidewire technology. The BetaWire(TM) is a super-torque interventional guidewire manufactured from a Beta Titanium alloy. Guidewires are thin, flexible wires that are used to facilitate the placement of balloon catheters and other diagnostic and therapeutic devices during coronary or peripheral interventional procedures.

"This is truly break through guidewire technology not seen before," said Steve Nuss, MMDI's Chief Marketing Officer. "Beta Titanium is an ideal alloy for interventional guidewires, its unique properties combine the best attributes found in conventional guidewire alloys such as Nitinol and stainless steel," he added.

Interventional Cardiologists that have evaluated the BetaWire for MMDI have been extremely impressed with its performance attributes such as precise one-to-one torque transmission, guidewire advancement, tip shaping and retention, flexibility and kink resistance.

MMDI has worked diligently to receive issuance of this U.S. patent. Millions of interventional guidewires are used every year throughout the world and MMDI believes that the BetaWire has the potential to make a significant impact on the market. Separately, MMDI also expects to receive international patent protection for the BetaWire in the very near future.

The Company will be seeking potential strategic partners for licensing, sales or distribution of their guidewire technology.

Additional information can be obtained by contacting Steve Nuss, Chief Marketing Officer at 763-354-7105 or snuss@2mdinc.com. You may also visit our website at: www.2mdinc.com.

About MMDI

MMDI was established in 2001 and is based in Plymouth, Minnesota. Located in the heart of Minnesota's "Medical Alley," MMDI has access to some of the world's finest medical product development, manufacturing and marketing resources. The Company's primary objective is to identify, develop, patent and manufacture unique medical devices that provide significant clinical benefits and market opportunities.



NEWS SOURCE: Minnesota Medical Development, Inc.

Send2Press® is the originating wire service for this story.

PRESS RELEASE PERMALINK: http://www.send2press.com/newswire/2008-11-1119-002.shtml

For more information about this news release, contact Minnesota Medical Development, Inc. directly through their Web site found in the above press release, and NOT Send2Press.

Copyright © 2008 by Send2Press® Newswire, part of the Neotrope® News Network (California, USA). All rights reserved. License/Terms of Use: Attribution Required ("Send2Press® is the originating wire service").